Skip to Content

Teriflunomide Dosage

Medically reviewed on July 13, 2018.

Applies to the following strengths: 14 mg; 7 mg

Usual Adult Dose for Multiple Sclerosis

7 mg or 14 mg orally once a day

Use: Treatment of patients with relapsing forms of multiple sclerosis.

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

-Mild and moderate hepatic impairment: No adjustment recommended
-Severe hepatic impairment: Contraindicated


Hepatotoxicity: Severe liver injury including fatal liver failure has been reported in patients treated with leflunomide, which is indicated for rheumatoid arthritis. A similar risk would be expected for teriflunomide because recommended doses of teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide.
-Obtain transaminase and bilirubin levels within 6 months before initiation of treatment and monitor ALT levels at least monthly for six months.
-If drug induced liver injury is suspected, discontinue treatment and start accelerated elimination procedure.

Risk of Teratogenicity: Based on animal data, teriflunomide may cause major birth defects if used during pregnancy.
-This drug is contraindicated in pregnant women or women of childbearing potential who are not using reliable contraception.
-Pregnancy must be avoided during treatment.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available.

Other Comments

Administration advice: Administer with or without food.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.